Ranked GEO Datasets

Scores and metadata are strong enough for direct review.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores and metadata are strong enough for direct review.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Scores are usable, but sample metadata contains review-only concerns.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 35%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: multi-cancer cohort is only secondary for colorectal ranking.
• Processed data is available for downstream review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 25%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 55%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 55%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 50%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 100%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 100%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 55%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Prioritized disease context: colorectal, colon, rectal, or CRC metadata detected.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 20%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
• Processed data is available for downstream review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 20%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
• Processed data is available for downstream review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 20%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 20%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 15%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs matched normal · Tissue · suitability 10%.
• Prioritized for patient tissue tumor-vs-normal triage.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 1 warning require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 3 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.

Dataset can inform exploration but is not strong enough for primary analysis.

• Tumor vs unmatched normal · Tissue · suitability 5%.
• Prioritized assay: bulk RNA-seq is the active assay expectation.
• Downgraded disease context: colorectal/GI relevance is unclear.
• Processed data is available for downstream review.
• 2 warnings require review.